Clinical RCT 2014 Phase 2b RCT in postoperative ileus (bowel resection inpatients) Beck, Sweeney, and McCarter (Ipamorelin 201 Study Group) reported a multicenter, double-blind, placebo-controlled proof-of-concept study in bowel-resection inpatients
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials
Tesamorelin clears it, providing the primary release GH drive and setting the pulse ceiling
Treatment protocols will continue to be refined for maximum effectiveness and patient benefit
Results may vary from person to person, so it would be better to continue until you get your desired results
Nat Med